CORMEDIX INC. (NYSEMKT:CRMD) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
its operating results for the first quarter ended March 31, 2017.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein in its entirety by reference.
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release dated May 10, 2017.
|
About CORMEDIX INC. (NYSEMKT:CRMD)
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation. CORMEDIX INC. (NYSEMKT:CRMD) Recent Trading Information
CORMEDIX INC. (NYSEMKT:CRMD) closed its last trading session up +0.008 at 0.532 with 644,404 shares trading hands.
